CO2018006929A2 - "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer" - Google Patents

"compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"

Info

Publication number
CO2018006929A2
CO2018006929A2 CONC2018/0006929A CO2018006929A CO2018006929A2 CO 2018006929 A2 CO2018006929 A2 CO 2018006929A2 CO 2018006929 A CO2018006929 A CO 2018006929A CO 2018006929 A2 CO2018006929 A2 CO 2018006929A2
Authority
CO
Colombia
Prior art keywords
cancer
treatment
thiadiazole compounds
methoxy
hydrogen
Prior art date
Application number
CONC2018/0006929A
Other languages
English (en)
Inventor
Mark David Charles
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
James Matthew Wood
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CO2018006929A2 publication Critical patent/CO2018006929A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DE 1,3,4-TIADIAZOL Y SU USO EN EL TRATAMIENTO DEL CÁNCER" Un compuesto de Fórmula (I): (I) o una sal farmacéuticamente aceptable del mismo, en la que: Q puede ser 5-metilpiridazin-3-ilo, 5-cloropiridazin-3-ilo, 6-metilpiridazin-3-ilo, o 6-fluoropiridazin-3-ilo; R puede ser hidrógeno, flúor, o metoxi; R1 puede ser hidrógeno, metoxi, difluorometoxi, o trifluorometoxi; y R2 puede ser metilo o etilo. El compuesto de fórmula (I) puede inhibir la glutaminasa, por ejemplo, GLS1.
CONC2018/0006929A 2015-11-30 2018-06-29 "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer" CO2018006929A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CO2018006929A2 true CO2018006929A2 (es) 2018-10-10

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006929A CO2018006929A2 (es) 2015-11-30 2018-06-29 "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"

Country Status (25)

Country Link
US (1) US9938265B2 (es)
EP (1) EP3383871B1 (es)
JP (1) JP6873132B2 (es)
KR (1) KR20180083412A (es)
CN (1) CN108349967B (es)
AR (1) AR106876A1 (es)
AU (1) AU2016363719B2 (es)
BR (1) BR112018010812A2 (es)
CA (1) CA3005516C (es)
CL (1) CL2018001408A1 (es)
CO (1) CO2018006929A2 (es)
DK (1) DK3383871T3 (es)
DO (1) DOP2018000134A (es)
EA (1) EA201891240A1 (es)
ES (1) ES2759940T3 (es)
IL (1) IL258644A (es)
MX (1) MX2018006528A (es)
NI (1) NI201800065A (es)
PE (1) PE20181450A1 (es)
PH (1) PH12018501132A1 (es)
SG (1) SG11201803813UA (es)
SV (1) SV2018005701A (es)
TN (1) TN2018000126A1 (es)
TW (1) TW201730188A (es)
WO (1) WO2017093300A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
WO2020078350A1 (zh) * 2018-10-16 2020-04-23 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377011T1 (de) * 1999-11-24 2007-11-15 Merck & Co Inc Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
US8003806B2 (en) * 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
MA33224B1 (fr) * 2009-04-20 2012-04-02 Hoffmann La Roche Derives de proline comme inhibiteurs de la cathepsine
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
DK2920168T3 (da) * 2012-11-16 2021-10-18 Calithera Biosciences Inc Heterocykliske glutaminase-inhibitorer
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6783663B2 (ja) * 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
US20150258082A1 (en) * 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
CN108349967B (zh) 2022-02-15
CA3005516A1 (en) 2017-06-08
EA201891240A1 (ru) 2018-11-30
EP3383871A1 (en) 2018-10-10
DK3383871T3 (da) 2019-12-16
CN108349967A (zh) 2018-07-31
AU2016363719A1 (en) 2018-07-05
EP3383871B1 (en) 2019-09-11
KR20180083412A (ko) 2018-07-20
US20170152254A1 (en) 2017-06-01
IL258644A (en) 2018-06-28
CL2018001408A1 (es) 2018-10-12
BR112018010812A2 (pt) 2018-11-27
NI201800065A (es) 2018-10-18
SV2018005701A (es) 2018-11-27
PE20181450A1 (es) 2018-09-12
JP6873132B2 (ja) 2021-05-19
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
SG11201803813UA (en) 2018-06-28
AU2016363719A8 (en) 2018-07-12
MX2018006528A (es) 2019-05-15
AU2016363719B2 (en) 2019-11-14
JP2019501134A (ja) 2019-01-17
CA3005516C (en) 2024-04-16
TN2018000126A1 (en) 2019-10-04
ES2759940T8 (es) 2020-05-20
DOP2018000134A (es) 2018-06-30
ES2759940T3 (es) 2020-05-12
TW201730188A (zh) 2017-09-01
AR106876A1 (es) 2018-02-28
PH12018501132A1 (en) 2019-01-21

Similar Documents

Publication Publication Date Title
CR20200376A (es) Inhibidores de cd73
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
GEP20237506B (en) Pcsk9 antagonist compounds
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AR103680A1 (es) Inhibidores selectivos de bace1
EA201791304A1 (ru) Производные изохинолина для лечения вич
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
CL2017001209A1 (es) Inhibidor de cinasa aurora a
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
PH12017500487A1 (en) Use of heterocyclic fluoroalkenyl sulfone compounds for repelling molluscs
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
CL2008001886A1 (es) Uso de compuestos derivado de tiofeno-benzimidazol de formula 1 definida o una sal del mismo para preparar un medicamento util para eltratamiento de un tumor snc primario en un mamifero que lo necesita.